Jonathan Alhalel, Nicolás Francone, Sharon Post, Catherine A. O’Brian, PhD, and Melissa A. Simon, MD, MPH
Underrepresentation of individuals with limited English proficiency who speak Spanish is ongoing in phase 3 biomedical clinical trials and exacerbates health inequity.
AMA J Ethics. 2022;24(4):E319-325. doi:
10.1001/amajethics.2022.319.
Fragmentation in US health care delivery streams and shortcomings in formal quality measures mean that transparency could be more useful to policymakers and regulators than patients.
AMA J Ethics. 2022;24(11):E1075-1082. doi:
10.1001/amajethics.2022.1075.
Sarosh Nagar, Leah Z. Rand, PhD, and Aaron S. Kesselheim, MD, JD, MPH
This article analyzes differences in prescription drug pricing transparency practices among 3 Organisation of Economic Co-operation and Development member nations.
AMA J Ethics. 2022;24(11):E1083-1090. doi:
10.1001/amajethics.2022.1083.
Mollie Gordon, MD, Rebecca Chen, MD, John Coverdale, MD, MEd, Mike Schiller, CRMP, Hanni Stoklosa, MD, MPH, and Phuong Nguyen, PhD
Little attention has been given to roles played by human trafficking in health care organizations’ supply chains of key equipment, such as hand sanitizers and gloves.
AMA J Ethics. 2024;26(4):E348-356. doi:
10.1001/amajethics.2024.348.